Critical Research Organisation Services – Invitation to Tender

Critical Research Organisation Services – Invitation to Tender

Clinical Research Organisation Services for a Vaccine Clinical Trial.

United Kingdom-York: Research and development services and related consultancy services

2019/S 186-452500

Contract notice

Services

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1)Name and addresses

University of York
Heslington
York
YO10 5DD
United Kingdom
Contact person: Procurement Office
Telephone: +44 1904328211
E-mail: dom.roebuck@york.ac.uk
NUTS code: 00
Internet address(es):Main address: www.york.ac.uk

Address of the buyer profile: https://in-tendhost.co.uk/york/

I.2)Information about joint procurement

I.3)Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at: https://in-tendhost.co.uk/york/aspx/Home
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be submitted to the abovementioned address

I.4)Type of the contracting authority

Body governed by public law

I.5)Main activity

Education

Section II: Object

II.1)Scope of the procurement

II.1.1)Title:

Clinical Research Organisation Services for a Vaccine Clinical Trial

Reference number: UY/PROC/657

II.1.2)Main CPV code

73000000

II.1.3)Type of contract

Services

II.1.4)Short description:

The University of York (‘the University’) is pleased to invite tenders for the provision of clinical research organisation services in accordance with the UY/PROC/657 invitation to tender (ITT) document.

II.1.5)Estimated total value

Value excluding VAT: 450 000.00 GBP

II.1.6)Information about lots

This contract is divided into lots: no
II.2)Description
II.2.1)Title:
II.2.2)Additional CPV code(s)

II.2.3)Place of performance

NUTS code: 00
Main site or place of performance:

II.2.4)Description of the procurement:

The aim of the study is to assess the safety and efficacy of single dose vaccination with ChAd63-KH for the prevention of PKDL in VL patients completing treatment with SSG/PM. The study is designed as a Phase II randomised controlled double blind trial (LEISH3; n = 262 patients in 2 arms) with an early safety evaluation and an interim analysis for futility.

II.2.5)Award criteria

Criteria below
Price
II.2.6)Estimated value

II.2.7)Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 42
This contract is subject to renewal: no

II.2.10)Information about variants

Variants will be accepted: yes

II.2.11)Information about options

Options: no
II.2.12)Information about electronic catalogues

II.2.13)Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: yes
Identification of the project:

European and Developing Countries Clinical Trials Partnership

II.2.14)Additional information

Section III: Legal, economic, financial and technical information

III.1)Conditions for participation

III.1.1)Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions:
III.1.2)Economic and financial standing
III.1.3)Technical and professional ability
III.1.5)Information about reserved contracts
III.2)Conditions related to the contract
III.2.1)Information about a particular profession
III.2.2)Contract performance conditions:
III.2.3)Information about staff responsible for the performance of the contract

Section IV: Procedure

IV.1)Description

IV.1.1)Type of procedure

Open procedure
IV.1.3)Information about a framework agreement or a dynamic purchasing system
IV.1.4)Information about reduction of the number of solutions or tenders during negotiation or dialogue
IV.1.6)Information about electronic auction

IV.1.8)Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes
IV.2)Administrative information
IV.2.1)Previous publication concerning this procedure

IV.2.2)Time limit for receipt of tenders or requests to participate

Date: 28/10/2019
Local time: 12:00
IV.2.3)Estimated date of dispatch of invitations to tender or to participate to selected candidates

IV.2.4)Languages in which tenders or requests to participate may be submitted:

English
IV.2.6)Minimum time frame during which the tenderer must maintain the tender

IV.2.7)Conditions for opening of tenders

Date: 28/10/2019
Local time: 12:05
Place:

Section VI: Complementary information

VI.1)Information about recurrence

This is a recurrent procurement: yes
VI.2)Information about electronic workflows
VI.3)Additional information:
VI.4)Procedures for review

VI.4.1)Review body

Royal Courts of Justice
Strand
London
WC2A 2LL
United Kingdom
Telephone: +44 2079476000
VI.4.2)Body responsible for mediation procedures

VI.4.3)Review procedure

Precise information on deadline(s) for review procedures:

VI.4.4)Service from which information about the review procedure may be obtained

University of York
Heslington
York
YO10 5DD
United Kingdom

VI.5)Date of dispatch of this notice:

24/09/2019